Labs by division
Hruska Lab
Keith A. Hruska, MD
Division of Nephrology, Hypertension & Pheresis
Our laboratory’s focus is the pathogenesis and pathophysiologic mechanisms of the chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney diseases produce a complex set of body-wide complications. Some of these contribute to the mortality of kidney diseases, which is not due to the disease itself but largely due to associated cardiovascular disease. Cardiovascular disease risk in CKD is contributed to by non-traditional risk factors which are components of the CKD-MBD syndrome.
Hruz Lab
Paul W. Hruz, MD, PhD
Division of Endocrinology & Diabetes
Our research efforts are directed toward understanding facilitative glucose transport as it relates to normal and disordered glucose homeostasis. A primary effort in our laboratory is the determination of structure/function relationships within the facilitative glucose transport proteins (GLUTs). We are using state of the art chemical and biophysical approaches to the determination of tertiary and quaternary structures of the human erythrocyte glucose transporter GLUT1 and the insulin responsive glucose transporter GLUT4.
In addition, we are also investigating the in vitro and in vivo effects of HIV protease inhibitors (PIs)on GLUT function. The goal of this research is to identify the molecular mechanisms that lead HIV infected patients receiving PIs to develop insulin resistance.
Hunstad Lab
David A. Hunstad, MD
Division of Infectious Diseases
Work in our lab focuses on the interactions of pathogenic Gram-negative bacteria with their hosts, using urinary tract infection (UTI) as our primary model. We aim to elucidate host-pathogen interactions in the urinary tract, modulation of host immune responses by uropathogenic bacteria, and the influence of sex on UTI pathogenesis.
Janowski Lab
Andrew Janowski, MD, MSCI
Division of Infectious Diseases
The COVID-19 pandemic will not be the last pandemic, as human populations will remain susceptible to newly emerging viruses. While the techniques for viral discovery have greatly expanded the number of known viral sequences, many fundamental questions regarding the biology of viruses can only be addressed through isolation and propagation of viruses in the laboratory setting.
Kao Lab
Carol M. Kao, MD
Division of Infectious Diseases
The Kao lab is interested in vaccine effectiveness, particularly in special populations.
Katira Lab
Bhushan Katira, MBBS
The Katira lab’s research focuses on novel mechanisms of lung injury associated with mechanical ventilation and critical care as well as developing strategies for personalized respiratory support and lung protection during critical illness. We have an expertise in using large animal models for developing translational research in critical illness as well as the application and development of advanced cardio-respiratory research tools such electrical impedance tomography.
Liss Lab
Kim Hung Ho Liss, MD
Division of Gastroenterology, Hepatology & Nutrition
Childhood liver disease; liver transplantation; nonalcoholic fatty liver disease; ischemia-reperfusion injury
Lowe Lab
Mark E. Lowe, MD, PhD
Division of Gastroenterology, Hepatology & Nutrition
Dietary fat digestion and mechanisms of chronic pancreatitis.
Luke-Pak-Silverman Lab
Clifford J. Luke, PhD
Stephen C. Pak, PhD
Gary A. Silverman, MD, PhD
Division of Newborn Medicine
We are a multi-PI lab with a primary interest in understanding the role of serpins (serine proteinase inhibitors) in normal physiology and disease. Serpins play important roles in maintaining cellular homeostasis by regulating the activity of their target proteases. As such, an imbalance in the protease-serpin equilibrium can lead to cellular dysfunction, tissue damage and death.
Luke research profile
Pak research profile
Silverman research profile
Magee Lab
Jeffrey Magee, MD, PhD
Division of Hematology & Oncology
The Magee lab is working to answer several important questions that surround the causes of childhood leukemia. How do childhood leukemias arise from normal blood forming stem cells? How do leukemia cells hijack normal stem cell programs? Why do childhood and adult leukemias have different mutations? Can we identify and target programs that maintain leukemia cells that are unique to childhood leukemia?